Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis
Summary This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behçet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) (P
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2008-06, Vol.141 (5), p.716-719 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 719 |
|---|---|
| container_issue | 5 |
| container_start_page | 716 |
| container_title | British journal of haematology |
| container_volume | 141 |
| creator | Ricart, José M. Ramón, Luis A. Vayá, Amparo España, Francisco Santaolaria, Maria‐Luisa Todolí, José Castelló, Remedios Fontcuberta, Jordi Estellés, Amparo |
| description | Summary
This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behçet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) (P |
| doi_str_mv | 10.1111/j.1365-2141.2008.07078.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69203255</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69203255</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3978-afe464a5421b3b6ac0a49b9f2029b7d9d5207f17b24a4bf4937bad7073ce49653</originalsourceid><addsrcrecordid>eNqNkM1u1DAQgC0EokvhFZAvcEs6_smPDxxoRWlRJS5wtmzHUbxK4sWTpd0n6oPwYjjdVbniy1ieb8YzHyGUQcnyudiWTNRVwZlkJQdoS2igacuHF2TznHhJNgDQFAxke0beIG4BmICKvSZnrBWS1YJtyHAdbApzHA9LcDTMQ7BhiYmO_rcfkZq5o7ucnGLaDQEnzAi99MOfR7_QLqA36J-gZfAhUYMYXTBLiDO9D8uQn1OcbMSAb8mr3ozo353iOfl5_eXH1U1x9_3r7dXnu8IJ1bSF6b2spakkZ1bY2jgwUlnVc-DKNp3qKg5NzxrLpZG2l0o01nR5e-G8VHUlzsnHY99dir_2Hhc9BXR-HM3s4x51rTgIXq1gewRdiojJ93qXwmTSQTPQq2W91atMvcrUq2X9ZFk_5NL3pz_2dvLdv8KT1gx8OAEGnRn7ZGYX8JnLE1RKgsjcpyN3H0Z_-O8B9OW3m_Um_gJN8ppk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69203255</pqid></control><display><type>article</type><title>Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ricart, José M. ; Ramón, Luis A. ; Vayá, Amparo ; España, Francisco ; Santaolaria, Maria‐Luisa ; Todolí, José ; Castelló, Remedios ; Fontcuberta, Jordi ; Estellés, Amparo</creator><creatorcontrib>Ricart, José M. ; Ramón, Luis A. ; Vayá, Amparo ; España, Francisco ; Santaolaria, Maria‐Luisa ; Todolí, José ; Castelló, Remedios ; Fontcuberta, Jordi ; Estellés, Amparo</creatorcontrib><description>Summary
This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behçet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) (P < 0·001) and plasminogen activator inhibitor‐1 (PAI‐1) levels (P = 0·022) were significantly higher in 79 patients than in 84 controls. No significant differences were observed in CPB2 (TAFI) Thr325Ile and SERPINE1 (PAI1) 4G/5G polymorphism distribution between patients and controls. TAFI activity levels were significantly higher in patients with thrombosis than in those without thrombosis (P = 0·024). In conclusion, the increased TAFI levels in Behçet disease could contribute to the increased risk of thrombosis observed in these patients.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/j.1365-2141.2008.07078.x</identifier><identifier>PMID: 18341631</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Behcet Syndrome - blood ; Behcet Syndrome - genetics ; Behçet disease ; Biological and medical sciences ; Blood Glucose - analysis ; Carboxypeptidase B2 - blood ; Female ; Fibrinolysis ; fibrinolytic inhibitors ; Genetic Predisposition to Disease ; Hematologic and hematopoietic diseases ; Humans ; Lipids - blood ; Male ; Medical sciences ; Middle Aged ; plasminogen activator inhibitor 1 ; Plasminogen Activator Inhibitor 1 - blood ; Polymorphism, Genetic ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; thrombin activatable fibrinolysis inhibitor ; Thrombosis - blood ; Thrombosis - genetics</subject><ispartof>British journal of haematology, 2008-06, Vol.141 (5), p.716-719</ispartof><rights>2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3978-afe464a5421b3b6ac0a49b9f2029b7d9d5207f17b24a4bf4937bad7073ce49653</citedby><cites>FETCH-LOGICAL-c3978-afe464a5421b3b6ac0a49b9f2029b7d9d5207f17b24a4bf4937bad7073ce49653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2141.2008.07078.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2141.2008.07078.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20359403$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18341631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ricart, José M.</creatorcontrib><creatorcontrib>Ramón, Luis A.</creatorcontrib><creatorcontrib>Vayá, Amparo</creatorcontrib><creatorcontrib>España, Francisco</creatorcontrib><creatorcontrib>Santaolaria, Maria‐Luisa</creatorcontrib><creatorcontrib>Todolí, José</creatorcontrib><creatorcontrib>Castelló, Remedios</creatorcontrib><creatorcontrib>Fontcuberta, Jordi</creatorcontrib><creatorcontrib>Estellés, Amparo</creatorcontrib><title>Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behçet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) (P < 0·001) and plasminogen activator inhibitor‐1 (PAI‐1) levels (P = 0·022) were significantly higher in 79 patients than in 84 controls. No significant differences were observed in CPB2 (TAFI) Thr325Ile and SERPINE1 (PAI1) 4G/5G polymorphism distribution between patients and controls. TAFI activity levels were significantly higher in patients with thrombosis than in those without thrombosis (P = 0·024). In conclusion, the increased TAFI levels in Behçet disease could contribute to the increased risk of thrombosis observed in these patients.</description><subject>Adult</subject><subject>Behcet Syndrome - blood</subject><subject>Behcet Syndrome - genetics</subject><subject>Behçet disease</subject><subject>Biological and medical sciences</subject><subject>Blood Glucose - analysis</subject><subject>Carboxypeptidase B2 - blood</subject><subject>Female</subject><subject>Fibrinolysis</subject><subject>fibrinolytic inhibitors</subject><subject>Genetic Predisposition to Disease</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Lipids - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>plasminogen activator inhibitor 1</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Polymorphism, Genetic</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>thrombin activatable fibrinolysis inhibitor</subject><subject>Thrombosis - blood</subject><subject>Thrombosis - genetics</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM1u1DAQgC0EokvhFZAvcEs6_smPDxxoRWlRJS5wtmzHUbxK4sWTpd0n6oPwYjjdVbniy1ieb8YzHyGUQcnyudiWTNRVwZlkJQdoS2igacuHF2TznHhJNgDQFAxke0beIG4BmICKvSZnrBWS1YJtyHAdbApzHA9LcDTMQ7BhiYmO_rcfkZq5o7ucnGLaDQEnzAi99MOfR7_QLqA36J-gZfAhUYMYXTBLiDO9D8uQn1OcbMSAb8mr3ozo353iOfl5_eXH1U1x9_3r7dXnu8IJ1bSF6b2spakkZ1bY2jgwUlnVc-DKNp3qKg5NzxrLpZG2l0o01nR5e-G8VHUlzsnHY99dir_2Hhc9BXR-HM3s4x51rTgIXq1gewRdiojJ93qXwmTSQTPQq2W91atMvcrUq2X9ZFk_5NL3pz_2dvLdv8KT1gx8OAEGnRn7ZGYX8JnLE1RKgsjcpyN3H0Z_-O8B9OW3m_Um_gJN8ppk</recordid><startdate>200806</startdate><enddate>200806</enddate><creator>Ricart, José M.</creator><creator>Ramón, Luis A.</creator><creator>Vayá, Amparo</creator><creator>España, Francisco</creator><creator>Santaolaria, Maria‐Luisa</creator><creator>Todolí, José</creator><creator>Castelló, Remedios</creator><creator>Fontcuberta, Jordi</creator><creator>Estellés, Amparo</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200806</creationdate><title>Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis</title><author>Ricart, José M. ; Ramón, Luis A. ; Vayá, Amparo ; España, Francisco ; Santaolaria, Maria‐Luisa ; Todolí, José ; Castelló, Remedios ; Fontcuberta, Jordi ; Estellés, Amparo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3978-afe464a5421b3b6ac0a49b9f2029b7d9d5207f17b24a4bf4937bad7073ce49653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Behcet Syndrome - blood</topic><topic>Behcet Syndrome - genetics</topic><topic>Behçet disease</topic><topic>Biological and medical sciences</topic><topic>Blood Glucose - analysis</topic><topic>Carboxypeptidase B2 - blood</topic><topic>Female</topic><topic>Fibrinolysis</topic><topic>fibrinolytic inhibitors</topic><topic>Genetic Predisposition to Disease</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Lipids - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>plasminogen activator inhibitor 1</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Polymorphism, Genetic</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>thrombin activatable fibrinolysis inhibitor</topic><topic>Thrombosis - blood</topic><topic>Thrombosis - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ricart, José M.</creatorcontrib><creatorcontrib>Ramón, Luis A.</creatorcontrib><creatorcontrib>Vayá, Amparo</creatorcontrib><creatorcontrib>España, Francisco</creatorcontrib><creatorcontrib>Santaolaria, Maria‐Luisa</creatorcontrib><creatorcontrib>Todolí, José</creatorcontrib><creatorcontrib>Castelló, Remedios</creatorcontrib><creatorcontrib>Fontcuberta, Jordi</creatorcontrib><creatorcontrib>Estellés, Amparo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ricart, José M.</au><au>Ramón, Luis A.</au><au>Vayá, Amparo</au><au>España, Francisco</au><au>Santaolaria, Maria‐Luisa</au><au>Todolí, José</au><au>Castelló, Remedios</au><au>Fontcuberta, Jordi</au><au>Estellés, Amparo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2008-06</date><risdate>2008</risdate><volume>141</volume><issue>5</issue><spage>716</spage><epage>719</epage><pages>716-719</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>Summary
This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behçet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) (P < 0·001) and plasminogen activator inhibitor‐1 (PAI‐1) levels (P = 0·022) were significantly higher in 79 patients than in 84 controls. No significant differences were observed in CPB2 (TAFI) Thr325Ile and SERPINE1 (PAI1) 4G/5G polymorphism distribution between patients and controls. TAFI activity levels were significantly higher in patients with thrombosis than in those without thrombosis (P = 0·024). In conclusion, the increased TAFI levels in Behçet disease could contribute to the increased risk of thrombosis observed in these patients.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>18341631</pmid><doi>10.1111/j.1365-2141.2008.07078.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2008-06, Vol.141 (5), p.716-719 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69203255 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Behcet Syndrome - blood Behcet Syndrome - genetics Behçet disease Biological and medical sciences Blood Glucose - analysis Carboxypeptidase B2 - blood Female Fibrinolysis fibrinolytic inhibitors Genetic Predisposition to Disease Hematologic and hematopoietic diseases Humans Lipids - blood Male Medical sciences Middle Aged plasminogen activator inhibitor 1 Plasminogen Activator Inhibitor 1 - blood Polymorphism, Genetic Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis thrombin activatable fibrinolysis inhibitor Thrombosis - blood Thrombosis - genetics |
| title | Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T22%3A20%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibrinolytic%20inhibitor%20levels%20and%20polymorphisms%20in%20Beh%C3%A7et%20disease%20and%20their%20association%20with%20thrombosis&rft.jtitle=British%20journal%20of%20haematology&rft.au=Ricart,%20Jos%C3%A9%20M.&rft.date=2008-06&rft.volume=141&rft.issue=5&rft.spage=716&rft.epage=719&rft.pages=716-719&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1111/j.1365-2141.2008.07078.x&rft_dat=%3Cproquest_cross%3E69203255%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69203255&rft_id=info:pmid/18341631&rfr_iscdi=true |